Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancerMore about Open Access at the Crick
Authors listStelios Chrysostomou Rajat Roy Filippo Prischi Lucksamon Thamlikitkul Kathryn L Chapman Uwais Mufti Robert Peach Laifeng Ding David Hancock Christopher Moore Miriam Molina Arcas Francesco Mauri David J Pinato Joel M Abrahams Silvia Ottaviani Leandro Castellano Georgios Giamas Jennifer Pascoe Devmini Moonamale Sarah Pirrie Claire Gaunt Lucinda Billingham Neil M Steven Michael Cullen David Hrouda Mathias Winkler John Post Philip Cohen Seth J Salpeter Vered Bar Adi Zundelevich Shay Golan Dan Leibovici Romain Lara David R Klug Sophia N Yaliraki Mauricio Barahona Yulan Wang Julian Downward Mark Skehel Maruf MU Ali Michael J Seckl Olivier E Pardo
Toggle all authors (43)
Lung and bladder cancers are mostly incurable because of the early development of drug resistance and metastatic dissemination. Hence, improved therapies that tackle these two processes are urgently needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and metastasis in lung and bladder cancer cells. Silencing this kinase, through either RNA interference or CRISPR, sensitized tumor cells to chemotherapy and hindered metastasis in vitro and in vivo in a tail vein injection model. Drug screening revealed several floxacin antibiotics as potent RSK4 activation inhibitors, and trovafloxacin reproduced all effects of RSK4 silencing in vitro and in/ex vivo using lung cancer xenograft and genetically engineered mouse models and bladder tumor explants. Through x-ray structure determination and Markov transient and Deuterium exchange analyses, we identified the allosteric binding site and revealed how this compound blocks RSK4 kinase activation through binding to an allosteric site and mimicking a kinase autoinhibitory mechanism involving the RSK4's hydrophobic motif. Last, we show that patients undergoing chemotherapy and adhering to prophylactic levofloxacin in the large placebo-controlled randomized phase 3 SIGNIFICANT trial had significantly increased (P = 0.048) long-term overall survival times. Hence, we suggest that RSK4 inhibition may represent an effective therapeutic strategy for treating lung and bladder cancer.
Journal Science Translational Medicine
Issue number 602